Your browser doesn't support javascript.
loading
Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation - real-life data from a survey in Eastern Switzerland.
Maeder, Micha Tobias; König, Tabea; Bogdanovic, Sanja; Schneider, Irene; Eugster, Werner; Ammann, Peter; König, Marius; Beer, Jürg; Rickli, Hans.
Afiliación
  • Maeder MT; Cardiology Department, Kantonsspital St. Gallen, Switzerland.
  • König T; Cardiology Department, Kantonsspital St. Gallen, Switzerland.
  • Bogdanovic S; Cardiology Department, Kantonsspital St. Gallen, Switzerland.
  • Schneider I; Cardiology Department, Kantonsspital St. Gallen, Switzerland.
  • Eugster W; Herzteam Wil, Switzerland, and Aerztenetz "Xundart", Wil, Switzerland.
  • Ammann P; Cardiology Department, Kantonsspital St. Gallen, Switzerland.
  • König M; Internal Medicine Department, Kantonsspital Baden and Molecular Cardiology, University Hospital of Zurich, Switzerland.
  • Beer J; Internal Medicine Department, Kantonsspital St. Gallen, Switzerland.
  • Rickli H; Cardiology Department, Kantonsspital St. Gallen, Switzerland.
Swiss Med Wkly ; 147: w14503, 2017.
Article en En | MEDLINE | ID: mdl-29039622
ABSTRACT
AIM OF THE STUDY To better appreciate the role of the non-vitamin K oral anticoagulants (NOACs) for patients with non-valvular atrial fibrillation in Switzerland we aimed to assess the quality of vitamin K antagonist (VKA) anticoagulation in daily practice.

METHODS:

In a cross-sectional study, clinically stable patients on VKA treatment for non-valvular atrial fibrillation for at least 6 months, documentation of international normalised ratio (INR) values for at least 3 months and with at least two INR values were included. The percentage of INR values within the therapeutic range of 2.0 to 3.0 and the time in therapeutic range (TTR; Rosendaal method) and predictors for these measures of VKA anticoagulation quality were assessed.

RESULTS:

We studied 332 patients (62% male, mean age 74 ± 9 years) with median (interquartile range) CHA2DS2Vasc and HAS-BLED scores of 4 (3-5) and 3 (2-4) points. The median number of INR values per patient was 8 (5-14), and the average interval between INR measurements was 20 (13-27) days. The percentage of INR values between 2.0 and 3.0 was 67% (50-83%). The median TTR was 69% (51-89%), and TTR ≥65% was found in 202 (61%) patients. Independent predictors of ≥80% INR values between 2.0 and 3.0 included a longer interval between INR measurements and the non-use of spironolactone. The non-use of amiodarone and spironolactone and a longer interval between INR measurements were the only independent predictors of a TTR ≥65%.

CONCLUSIONS:

The quality of VKA anticoagulation in Switzerland is highly variable. Importantly, only 60% of patients achieve a TTR ≥65%, which is currently considered to be the minimal acceptable TTR required for VKA therapy. There are few clinical predictors of a good VKA anticoagulation quality. These data may represent a novel basis for decision making regarding the choice of anticoagulation for atrial fibrillation in Switzerland.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fibrilación Atrial / Vitamina K / Coagulación Sanguínea / Anticoagulantes Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: Swiss Med Wkly Asunto de la revista: MEDICINA Año: 2017 Tipo del documento: Article País de afiliación: Suiza

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fibrilación Atrial / Vitamina K / Coagulación Sanguínea / Anticoagulantes Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: Swiss Med Wkly Asunto de la revista: MEDICINA Año: 2017 Tipo del documento: Article País de afiliación: Suiza